The Ohio State University Wexner Medical Center's Heart and Vascular Center has named Dr. Garret FitzGerald, professor of Medicine and Pharmacology; chair of the Department of Pharmacology and director of the Institute for Translational Medicine and Therapeutics at the Perelman School of Medicine at University of Pennsylvania, the recipient of the 2013 Jay and Jeanie Schottenstein Prize in Cardiovascular Sciences.

An American Heart Association/American Stroke Association sponsored study comparing which stroke therapies work best has received a $2 million research award from the Patient-Centered Outcomes Research Institute (PCORI).

Bayer HealthCare today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development has granted two separate orphan drug designations for its investigational, oral medication riociguat, proposed trade name Adempas®, for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The Orphan Drug Designation program provides orphan status to drugs and biologics that are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases and disorders that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug.

Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the number of patients enrolled in the company's REDUCE-IT cardiovascular outcomes study of Vascepa(R) (icosapent ethyl) capsules has surpassed 6,000.

Certain congenital heart defects may raise children’s risk of developing infective endocarditis (IE), Canadian researchers found in a study published Sept. 24 in Circulation. Children with cyanotic congenital heart disease lesions, left-sided lesions and endocardial cushion defects were at highest risk for IE.

The FDA broadened the pool of patients with inoperable aortic valve stenosis by approving revised labeling for the Sapien Transcatheter Heart Valve. The agency based its decision in part on data from the Transcatheter Valve Therapy Registry.

The Canadian Medical Hall of Fame is proud to announce the 2014 inductees. Their passion and innovative, visionary leadership has improved health worldwide. The six inductees announced today will join the ranks of 101 laureates who have gone before them in receiving this prestigious national honour.

Atherotech Diagnostics Lab, a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions, announces the addition of Gerard Abate, M.D., as the company’s Chief Clinical Officer.